BAM
VYNE icon

Blueshift Asset Management’s VYNE Therapeutics VYNE Stock Holding History

Blueshift Asset Management’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-698
Closed -$86K – 1193
2021
Q1 		$86K Buy
+698
New +$101K 0.01% 817

Other funds holding VYNE

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return

Blueshift Asset Management's VYNE Position: Q2 2021 in Review

Blueshift Asset Management sold out of VYNE Therapeutics (VYNE) in Q2 2021, closing a stake of 698 shares — an estimated $86K sold.

Blueshift Asset Management first reported a position in VYNE in Q1 2021 and held it in 1 quarter. The position peaked at $86K in Q1 2021. 72 funds tracked by Wall St. Rank hold VYNE as of Q2 2021.

  • Blueshift Asset Management reported no remaining VYNE Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Blueshift Asset Management sold 698 VYNE Therapeutics shares in Q2 2021, an estimated $86K.
  • Blueshift Asset Management first reported a position in VYNE Therapeutics in Q1 2021 and held it in 1 quarter.
  • Blueshift Asset Management's VYNE Therapeutics position peaked at $86K in Q1 2021.
  • 72 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q2 2021.

Based on Blueshift Asset Management's 13F filing for Q2 2021, filed 13 Aug 2021.